RareCyte, Inc.

High-confidence spatial biology and liquid biopsy

[RareCyte, Inc. @RareCyte]

Join us on November 18 for a webinar featuring William Mifsud, PhD, Head of Pathology Research at Kite Pharma, as he shares how his team uses Orion™ multiplex immunofluorescence to assess combinatorial target expression across large tissue cohorts.

https://t.co/qrjq05ETrP

[RareCyte, Inc. @RareCyte]

🎉 RareCyte has been named one of hashtag#GEN Genetic Engineering & Biotechnology News Top 10 Spatial Biology Companies of 2026!

Read the full article: Top 10 Spatial Biology Companies
https://t.co/Y6EN5RXTKq

[RareCyte, Inc. @RareCyte]

Heading to #SITC2026? Explore how spatial proteomics is advancing immuno-oncology research, from understanding treatment response to characterizing the tumor microenvironment.

See featured spatial biology presentations at the conference: https://t.co/k2J2T03biT

[RareCyte, Inc. @RareCyte]

How well do circulating tumor cells (CTCs) reflect the biology of a patient’s tumor? 🤔

A new study from UW provides compelling evidence that CTC protein expression can reflect key tumor characteristics in patients with advanced prostate cancer.

https://t.co/vZlx1rtsrA

[RareCyte, Inc. @RareCyte]

Live from Biomarkers, CDx & Precision Medicine Europe 2026!

Come see how Orion™ supports high-plex spatial proteomics for precision therapeutics programs – visit us at Booth #47.

#BIOMEU2026 #BiomarkersEurope2026

[RareCyte, Inc. @RareCyte]

Great conversations around spatial proteomics for translational and clinical research at #ESSB2026!

Thank you to all who stopped by the RareCyte booth!

#ESSB #SpatialBiology

[RareCyte, Inc. @RareCyte]

Learn how to translate your research question into a custom spatial biomarker panel.

Next week, join a short webinar focused on designing panels for the Orion™ spatial proteomics platform.

✅ See a live demo of the new Panel Designer tool

👉 Register: https://t.co/T6xn9omgk5

[RareCyte, Inc. @RareCyte]

Live from #BIOMUS2026 in San Diego!

Swing by the RareCyte booth this afternoon to explore how the Orion spatial proteomics platform helps advance biomarker development from translational research through clinical trials.

View conference info: https://t.co/8aMqC8ivuu

[RareCyte, Inc. @RareCyte]

Live from #JCA2026 in Kyoto, Japan!

Stop by Yamato's booth E-21 to explore the Orion spatial proteomics platform.

☑️Attend the luncheon seminar today at 12:15!
Spatial Proteomics: Unlocking New Insights into Cancer Biology

More details: https://t.co/1WS5yDNby3

@yamato_kagaku

[RareCyte, Inc. @RareCyte]

At #BIOMUS2026? Don’t miss Dr. Richard van Krieken’s presentation today at 2:55 PM on how high-plex spatial proteomics can generate actionable insights for clinical trials.

Presentation details: https://t.co/PrkO7ntdcO

#BiomarkersUS #SpatialBiology

[RareCyte, Inc. @RareCyte]

The challenge: turning spatial proteomics insights into clinically actionable results.

🔎 Here's how three oncology researchers are doing it with Orion™ spatial proteomics.

Read the blog ➡️ https://t.co/WWoEp0hbur

#SpatialBiology #MultiplexIF #SpatialProteomics

[RareCyte, Inc. @RareCyte]

Join us for a 30-minute live session focused on how to translate a biological research question into a custom spatial biomarker panel on the Orion spatial proteomics platform.

Plus, see a demo of the new Orion Panel Designer tool.

Register here: https://t.co/T6xn9omgk5

[RareCyte, Inc. @RareCyte]

Attending #ESSB in Barcelona? Visit RareCyte at booth #18 to explore how researchers use the Orion spatial proteomics platform to advance biomarker development from translational research through clinical trials.

See event details: https://t.co/aKXNCqusgc

#ESSB26 #ESSB2026

[RareCyte, Inc. @RareCyte]

Heading to #BiomarkersUS in San Diego? 🌴 Attend this presentation to hear how high-plex spatial proteomics is being applied in clinical trials.

📅 Sept 23 | 2:55-3:20pm
🗣️ Richard van Krieken, PhD, Navigate BioPharma Services

See presentation details ➡️https://t.co/8aMqC8ivuu

[RareCyte, Inc. @RareCyte]

Great conversations at our Orion seminar at the The @UBC this week!

Thank you to UBC Mapcore for hosting us!

We’re thrilled to keep the momentum around spatial proteomics going and support future projects.

#SpatialProteomics #SpatialBiology #OrionSpatial

[RareCyte, Inc. @RareCyte]

Orion enabled the research team to:

• Quantify intratumoral CD3⁺CD8⁺ T-cell infiltration
• Measure the CD8⁺/FOXP3⁺ T-cell ratio
• Resolve PD-L1 expression across macrophage and tumor-cell compartments
• Compare immune infiltration before and during treatment

[RareCyte, Inc. @RareCyte]

What distinguishes the immune microenvironment of a tumor that responds to treatment?

In phase 1/2 trial of Copanlisib + nivolumab in microsatellite-stable CRC, Orion provided subcellular imaging of 18 immune-focused markers.

Read publication ➡️ https://t.co/Rzm2VB1Dum

[RareCyte, Inc. @RareCyte]

2M+ babies are stillborn each year, yet many maternity care tools haven’t changed in decades.

We are proud to be part of @WellcomeLeap's In Utero program, an initiative with the goal of developing scalable solutions to reduce stillbirth rates by 50%.

[RareCyte, Inc. @RareCyte]

Can high-plex spatial proteomics deliver IHC-quality data?

Harvard and BWH researchers showed that 16- to 18-plex Orion panels produced staining patterns comparable to conventional IHC—and enabled diagnostic-quality H&E on the same tissue section.

https://t.co/wFl9tnXxA4

[RareCyte, Inc. @RareCyte]

Spatial proteomics provides critical insights into therapeutic response, but clinical research requires more than multiplex depth alone.

🎬 In this on-demand webinar, learn how Navigate BioPharma Services validated a 17-plex panel for clinical trials. ➡️https://t.co/jov3keBL1T